General Court of European Union Confirms Withdrawal Of Orphan Medicine Status Because Cancer Medicine Elotuzumab No Longer Offers Significant Benefit Over Alternative Treatment
- 14/01/2019
- Articles
On 5 December 2018, the General Court of the European Union dismissed an action for annulment of a decision of the European Commission which had found that elotuzumab, a medicine indicated for the treatment of multiple myeloma, no longer satisfied the criteria for designation as an orphan medicinal product.
Please find attached a case note which discusses this judgment.